Provided herein are compositions and their methods of use to adhere (e.g., in wet and dry environments) a variety of materials together.

Disclosed are hydrogels polymerized with or around a solid biofunctional moiety, biodegradable or permanent, designed to be implantable in a mammalian body, intended to block or mitigate the formation of tissue adhesions, and intended to aid in functional healing. The hydrogels of the present invention are characterized by comprising multiphasic structural elements: a) at least one gel phase, b) at least one solid phase, c) optional polymeric chains connecting gel and solid phases, d) optional shape designs that provide for an interpenetrating geometry between gels and solids, e) optional shape designs that enhance a tissue-hydrogel interface, and f) optional shape designs that provide a biofunctional aspect. The hydrophobicity of the various phases is chosen to reduce tissue adhesion and enhance tissue healing. The morphology of the polymers comprising the gel phase is typically of high molecular weight and has morphology that encourages entanglement. Useful polymeric structures include branching chains, comb or brush, and dendritic morphologies.

Medical devices are provided for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.

Embodiments of the invention include devices and coatings for devices including coated hydrophobic active agent particles. In an embodiment, the invention includes a drug delivery device including a substrate; and coated therapeutic agent particles disposed on the substrate, the coated therapeutic agent particles comprising a particulate hydrophobic therapeutic agent; and a cationic agent in contact with the particulate hydrophobic therapeutic agent. Other embodiments are also included herein.

The invention relates to a two-component system for the in situ preparation of a polymer network by polymerizing acrylate monomers in the presence of a redox initiator couple comprising an activator and an initiator, the system comprising a first container with a first component, which first component comprises the activator; and a second container with a second component, which second component comprises the initiator; wherein the activator and/or the initiator is dissolved in an aqueous buffer solution; and wherein one or both containers further comprise a water soluble acrylic monomer having one acrylate group; and a water soluble acrylic monomer having two or more acrylate groups; and at least one glycosaminoglycan; and wherein the combined water content in both containers is at least 50 wt. %, based on the total weight of the contents of both containers.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Provided are a method of manufacturing a stent for drug release that may be coated with a drug by forming a 3D nanostructured film on the surface of a stent and a stent for drug release manufactured thereby, more particularly, a method of manufacturing a stent for drug release including: (a) preparing a stent, (b) forming a 3D nanostructured film on a surface of the stent; and (c) surface-treating the 3D nanostructured film, and a stent for drug release manufactured thereby.

Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.

Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.